Plaque AnalysisWhat You DECIDE Shapes the Outcomes.
The Largest Prospective Registry on Plaque Analysis in Coronary Artery Disease (CAD)1
The DECIDE Registry is a landmark prospective study of ~22,000 patients at over 30 centers across the United States following outcomes through 1 year. DECIDE demonstrates how Heartflow Plaque Analysis empowers physicians with clinical insights that lead to real-world impact: faster, more durable LDL-C control, and fewer cardiovascular events compared to CCTA alone.1,2
What if Plaque Analysis could show which half of CCTA patients need a change in management?1
Traditional risk factors, such as age, family history, smoking, or hypertension, are useful for predicting CAD in populations but fall short at the individual level3,4 While CCTA alone is capable of visualizing plaque, conventional interpretation3-5 doesn't provide plaque quantity by type, which is proven to be a more accurate predictor of cardiac events.5 Plaque Analysis identifies and quantifies all plaque types, providing you with personalized data and Plaque Staging insights to determine which 50% of your patients require changes to their treatment plans.1
The DECIDE registry shows what happens next: Durable LDL-C control and fewer cardiovascular events at 1 year.2
The DECIDE registry shows what happens next: Durable LDL-C control and fewer cardiovascular events at 1 year.2
Plaque AnalysisInsights Built for Action in the DECIDE Registry
Medical management recommendations developed by preventive cardiology and CCTA expert consensus are being studied in the DECIDE Registry, the largest prospective registry on Plaque Analysis.1
Proven to Change Management,
Proven to Change Outcomes.1,2
In the DECIDE Registry patients managed using Heartflow s Plaque Analysis experienced faster, more durable LDL-C control, and fewer cardiovascular events compared to CCTA alone.
of patients, including ~⅓ of CAC 0 patients, had medical management changed when Plaque Analysis was added compared to their management based on CCTA alone.1
of patients achieved LDL-C goals (<70 mg/dL) by 90 days, vs. ~35% with CCTA alone, with goal attainment sustained through 1 year.2
fewer major vascular events at 1 year vs. CCTA alone, and half the rate of MI.2
of patients, including ~⅓ of CAC 0 patients, had medical management changed when Plaque Analysis was added compared to their management based on CCTA alone.1
of patients achieved LDL-C goals (<70 mg/dL) by 90 days, vs. ~35% with CCTA alone, with goal attainment sustained through 1 year.2
fewer major vascular events at 1 year vs. CCTA alone, and half the rate of MI.2
Heartflow Is the Proven Choice for Plaque
With the DECIDE Registry, Heartflow continues to deliver high-quality evidence, proving again our commitment to transforming how CAD is managed — one insight, one patient, and one decision at a time.
Download DECIDE Data SheetJoin the Movement Toward Smarter, Preventive Care
Whether you're looking to improve treatment plans, outcomes, or gain greater confidence in how you care for your patients, Heartflow's Plaque Analysis is the new standard in preventive CAD management. DECIDE what’s right for your patients today.